Rezolute, Inc.
RZLTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company carries a $441.0M market cap, placing it firmly in the small-cap category. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
Market Cap
$441.0M
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
-7.31
EPS (TTM)
$-0.81
EPS (Fwd)
$-0.63
ROE
-81.7%
ROA
-48.7%
Cash
$120.3M
Total Debt
$1.1M
Free CF
-$43.7M
52W Change
-43.3%
Annual Financials
Cash vs Debt
Where RZLT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RZLT finished 17.83% above its 150-day moving average ($3.87) and 9.09% above its 200-day moving average ($4.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RZLT overbought or oversold?
At the September 3, 2026 close, RZLT's RSI(14) was 48.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Rezolute, Inc. holds $120.3M in cash against $1.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$43.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -81.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.61 suggests RZLT is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, RZLT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Rezolute, Inc. and its sector.